Literature DB >> 16884969

Serotonin transporter and receptor expression in osteocytic MLO-Y4 cells.

M Bliziotes1, A Eshleman, B Burt-Pichat, X-W Zhang, J Hashimoto, K Wiren, C Chenu.   

Abstract

Neurotransmitter regulation of bone metabolism has been a subject of increasing interest and investigation. We reported previously that osteoblastic cells express a functional serotonin (5-HT) signal transduction system, with mechanisms for responding to and regulating uptake of 5-HT. The clonal murine osteocytic cell line, MLO-Y4, demonstrates expression of the serotonin transporter (5-HTT), and the 5-HT1A, and 5-HT2A receptors by real-time RT-PCR and immunoblot analysis. Immunohistochemistry using antibodies for the 5-HTT, and the 5-HT1A and 5-HT2A receptors reveals expression of all three proteins in both osteoblasts and osteocytes in rat tibia. 5-HTT binding sites were demonstrated in the MLO-Y4 cells with nanomolar affinity for the stable cocaine analog [125I]RTI-55. Imipramine and fluoxetine, antagonists with specificity for 5-HTT, show the highest potency to antagonize [125I]RTI-55 binding in the MLO-Y4 cells. GBR-12935, a relatively selective dopamine transporter antagonist, had a much lower potency, as did desipramine, a selective norepinephrine transporter antagonist. The maximal [3H]5-HT uptake rate in MLO-Y4 cells was 2.85 pmol/15 min/well, with a Km value of 290 nM. Imipramine and fluoxetine inhibited specific [3H]5-HT uptake with IC50 values in the nanomolar range. 5-HT rapidly stimulated PGE2 release from MLO-Y4 cells; the EC50 for 5-HT was 0.1 microM, with a 3-fold increase seen at 60 min. The rate-limiting enzyme for serotonin synthesis, tryptophan hydroxylase, is expressed in MLO-Y4 cells as well as osteoblastic MC3T3-E1 cells. Thus, osteocytes, as well as osteoblasts, are capable of 5-HT synthesis, and express functional receptor and transporter components of the 5-HT signal transduction system.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16884969      PMCID: PMC1766480          DOI: 10.1016/j.bone.2006.06.009

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  47 in total

1.  Evidence for a dense and intimate innervation of the bone tissue, including glutamate-containing fibers.

Authors:  C M Serre; D Farlay; P D Delmas; C Chenu
Journal:  Bone       Date:  1999-12       Impact factor: 4.398

2.  Peripheral patterns of calcitonin-gene-related peptide general somatic sensory innervation: cutaneous and deep terminations.

Authors:  L Kruger; J D Silverman; P W Mantyh; C Sternini; N C Brecha
Journal:  J Comp Neurol       Date:  1989-02-08       Impact factor: 3.215

3.  Bone histomorphometric and biomechanical abnormalities in mice homozygous for deletion of the dopamine transporter gene.

Authors:  M Bliziotes; S McLoughlin; M Gunness; F Fumagalli; S R Jones; M G Caron
Journal:  Bone       Date:  2000-01       Impact factor: 4.398

4.  Innervation of periosteum and bone by sympathetic vasoactive intestinal peptide-containing nerve fibers.

Authors:  E L Hohmann; R P Elde; J A Rysavy; S Einzig; R L Gebhard
Journal:  Science       Date:  1986-05-16       Impact factor: 47.728

5.  Neuro-hormonal control of bone metabolism: vasoactive intestinal peptide stimulates alkaline phosphatase activity and mRNA expression in mouse calvarial osteoblasts as well as calcium accumulation mineralized bone nodules.

Authors:  P Lundberg; I Boström; H Mukohyama; A Bjurholm; K Smans; U H Lerner
Journal:  Regul Pept       Date:  1999-11-30

6.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

7.  Effect of serotonin on prostaglandin synthesis in rat cultured mesangial cells.

Authors:  T Knauss; H E Abboud
Journal:  Am J Physiol       Date:  1986-11

8.  Molecular characterization of antipeptide antibodies against the 5-HT1A receptor: evidence for state-dependent antibody binding.

Authors:  T E Anthony; E C Azmitia
Journal:  Brain Res Mol Brain Res       Date:  1997-10-15

9.  Substance P- and CGRP-immunoreactive nerves in bone.

Authors:  A Bjurholm; A Kreicbergs; E Brodin; M Schultzberg
Journal:  Peptides       Date:  1988 Jan-Feb       Impact factor: 3.750

10.  A histological demonstration of nerves in subchondral bone.

Authors:  I Reimann; S B Christensen
Journal:  Acta Orthop Scand       Date:  1977
View more
  39 in total

Review 1.  Minireview: A skeleton in serotonin's closet?

Authors:  Masanobu Kawai; Clifford J Rosen
Journal:  Endocrinology       Date:  2010-07-21       Impact factor: 4.736

2.  A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys.

Authors:  Chadi A Calarge; Bridget Zimmerman; Diqiong Xie; Samuel Kuperman; Janet A Schlechte
Journal:  J Clin Psychiatry       Date:  2010-03       Impact factor: 4.384

3.  The serotonin 5-HT2B receptor controls bone mass via osteoblast recruitment and proliferation.

Authors:  C Collet; C Schiltz; V Geoffroy; L Maroteaux; J-M Launay; M-C de Vernejoul
Journal:  FASEB J       Date:  2007-09-10       Impact factor: 5.191

4.  Antidepressant use and 10-year incident fracture risk: the population-based Canadian Multicentre Osteoporosis Study (CaMoS).

Authors:  C Moura; S Bernatsky; M Abrahamowicz; A Papaioannou; L Bessette; J Adachi; D Goltzman; J Prior; N Kreiger; T Towheed; W D Leslie; S Kaiser; G Ioannidis; L Pickard; L-A Fraser; E Rahme
Journal:  Osteoporos Int       Date:  2014-02-25       Impact factor: 4.507

Review 5.  The gut microbiota--masters of host development and physiology.

Authors:  Felix Sommer; Fredrik Bäckhed
Journal:  Nat Rev Microbiol       Date:  2013-02-25       Impact factor: 60.633

6.  Variants of the serotonin transporter gene, selective serotonin reuptake inhibitors, and bone mineral density in risperidone-treated boys: a reanalysis of data from a cross-sectional study with emphasis on pharmacogenetics.

Authors:  Chadi A Calarge; Vicki L Ellingrod; Bridget Zimmerman; Michael M Bliziotes; Janet A Schlechte
Journal:  J Clin Psychiatry       Date:  2011-12       Impact factor: 4.384

7.  Use of anti-depressants and the risk of fracture of the hip or femur.

Authors:  M W M van den Brand; S Pouwels; M M Samson; T P van Staa; B Thio; C Cooper; H G M Leufkens; A C G Egberts; H J J Verhaar; F de Vries
Journal:  Osteoporos Int       Date:  2009-02-24       Impact factor: 4.507

8.  Dietary tryptophan manipulation reveals a central role for serotonin in the anabolic response of appendicular skeleton to physical activity in rats.

Authors:  Valeria Sibilia; Francesca Pagani; Elisa Dieci; Emanuela Mrak; Marcella Marchese; Guido Zarattini; Francesca Guidobono
Journal:  Endocrine       Date:  2013-04-26       Impact factor: 3.633

9.  Depressive symptoms, bone loss, and fractures in postmenopausal women.

Authors:  Leslie Spangler; Delia Scholes; Robert L Brunner; John Robbins; Susan D Reed; Katherine M Newton; Jennifer L Melville; Andrea Z Lacroix
Journal:  J Gen Intern Med       Date:  2008-02-20       Impact factor: 5.128

Review 10.  Do Selective Serotonin Reuptake Inhibitors (SSRIs) Cause Fractures?

Authors:  Stuart J Warden; Robyn K Fuchs
Journal:  Curr Osteoporos Rep       Date:  2016-10       Impact factor: 5.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.